Citi analyst Joanne Wuensch lowered the firm’s price target on Medtronic (MDT) to $110 from $117 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic: MiniMed IPO Dilution and Diabetes Spin-Off Limit Near-Term Upside, Justifying Hold Rating
- Medtronic price target lowered to $95 from $105 at Stifel
- Medtronic price target lowered to $115 from $125 at Argus
- Medtronic price target lowered to $108 from $115 at Evercore ISI
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls